THANK YOU FOR SUBSCRIBING
The funds raised will be invested to support the ongoing clinical development of FT-4202, FORMA's Pyruvate Kinase-R (PKR) activator in clinical development as a prospective disease-modifying therapy for sickle cell disease (SCD)
Fremont, CA: FORMA Therapeutics, a biopharmaceutical company focused on atypical hematologic diseases and cancers, raised $100 million in Series D round of financing. RA Capital Management led the financing round with participation from Wellington Management, Cormorant Asset Management, Samsara BioCapital, and funds managed by Janus Henderson Investors, and also by an undisclosed healthcare investment fund.
"This financing reflects our sharpened focus on serving patients with rare hematologic diseases and cancers," said Frank Lee, chief executive officer of FORMA Therapeutics. "In the last month, we have presented important proof of mechanism and differentiating clinical data for our programs in sickle cell disease, glioma, AML, and NASH. We are energized by the commitment from this group of leading industry investors as we move into 2020, another critical year with multiple clinical data readouts and a new program entering the clinic."
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
"We are impressed with FORMA's seamless transformation over the past year, moving from an early discovery engine to a clinical-stage, asset-focused company," said Peter Kolchinsky, Ph.D., managing partner of RA Capital Management and new FORMA board member. "We feel fortunate to be able to come together with our peers to capitalize on FORMA's development of what we believe are several best-in-class molecules. While there are already many programs in development to help patients with sickle cell disease and the cancers we are targeting, FORMA's candidates representing a unique and likely complementary contribution to the future armamentarium, which is important both for patients and strategically for FORMA."
The funds raised will be invested to support the ongoing clinical development of FT-4202, FORMA's Pyruvate Kinase-R (PKR) activator in clinical development as a prospective disease-modifying therapy for sickle cell disease (SCD). According to the data presented in the 2019 American Society of Hematology (ASH) Annual Meeting, it is confirmed that FT-4202 activates PKR with an immediate effect on hemoglobin oxygen affinity and adenosine triphosphate (ATP) levels, and it was protected and well-tolerated in healthy subjects. A Phase 1/2 study is presently enrolling patients with sickle cell disease.
The funding will also support FORMA's deep pipeline, including FT-7051, a novel and strong selective inhibitor of CBP/p300 fastening to DNA for androgen receptor-driven cancers, also being examined for its possibility in AR-v7 mCRPC; olutasidenib, a next-generation inhibitor of mutated isocitrate dehydrogenase 1 (IDH1m) in development to treat gliomas, relapsed/refractory acute myeloid leukemia (R/R AML), myelodysplastic syndrome (MDS) and other IDH1m solid tumors; and progress on a variety of preclinical programs.
See Also :- Top Healthcare Solution Companies

More in News